{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:57:38Z","timestamp":1790639858164,"version":"4.1.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Bevacizumab, originally developed by Genentech under the brand name\n                    <jats:italic>Avastin<\/jats:italic>\n                    <jats:sup>\u00ae<\/jats:sup>\n                    as an anti-cancer drug, has gained widespread off-label use in ophthalmology due to its similar mechanism of action to other anti-VEGF treatments and its significantly lower cost compared to available on label alternatives for ophthalmological indications. While off-label bevacizumab has been standard in clinical practice for over a decade, recently, a repurposed formulation (brand name:\n                    <jats:italic>Lytenava<\/jats:italic>\n                    <jats:sup>\u00ae<\/jats:sup>\n                    , Outlook Therapeutics Ltd), developed specifically for vascular retinal conditions, received marketing approval from the European Medicines Agency. This raises questions about what the price for a repurposed formulation should reasonably be, reflecting the efforts to obtain regulatory approval. This paper examines potential cost-based-plus pricing for such a repurposed formulation of bevacizumab using a novel pricing framework across four scenarios. By evaluating the pricing structure through an analysis of critical cost components, including, among others, research and development expenditures, manufacturing costs, and cost-of-capital, the study proposes a price range of \u20ac73 to \u20ac177 per injection. The explicit breakdown of these cost components provides valuable insights into the economic structure of repurposed biosimilars like bevacizumab, emphasizing how a cost-based-plus pricing model can support more transparent and informed negotiations between pharmaceutical companies and healthcare payers. Ultimately, this approach contributes to the development of pricing strategies that balance affordability for healthcare systems with sustainable returns for manufacturers while fostering the broader development of repurposed treatments. The findings of this paper aim to advance the dialogue on equitable pricing for repurposed therapies.\n                  <\/jats:p>","DOI":"10.1007\/s10198-025-01891-3","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T06:20:10Z","timestamp":1770445210000},"page":"1453-1467","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Repurposing biosimilars, rethinking costs: a framework for sustainable drug pricing for repurposed bevacizumab for intravitreal injections"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8200-3195","authenticated-orcid":false,"given":"Evert A.","family":"Manders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"van Der Wel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinier","family":"Schlingemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla E.M.","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saco J.","family":"de Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"issue":"14","key":"1891_CR1","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld, P.J., Brown, D.M., Heier, J.S., Boyer, D.S., Kaiser, P.K., Chung, C.Y., Kim, R.Y.: Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355(14), 1419\u20131431 (2006)","journal-title":"N. Engl. J. Med."},{"key":"1891_CR2","unstructured":"U.S. Food and Drug Administration: Lucentis (ranibizumab) [label information]. (2014). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125156s105lbl.pdf. Accessed 21 Nov 2024"},{"key":"1891_CR3","unstructured":"European Medicines Agency: Lucentis: EPAR \u2013 Medicine overview: (2018). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/lucentis-epar-medicine-overview_en.pdf. Accessed 21 Nov 2024"},{"issue":"6","key":"1891_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.4103\/0301-4738.36474","volume":"55","author":"S Grisanti","year":"2007","unstructured":"Grisanti, S., Ziemssen, F.: Bevacizumab: off-label use in ophthalmology. Indian J. Ophthalmol. 55(6), 417\u2013420 (2007). https:\/\/doi.org\/10.4103\/0301-4738.36474","journal-title":"Indian J. Ophthalmol."},{"key":"1891_CR5","first-page":"65","volume":"32","author":"RM Jansen","year":"2016","unstructured":"Jansen, R.M.: The off-label use of medication: The latest on the Avastin\u00ae\u2013Lucentis\u00ae debate. Med. Law 32, 65\u201374 (2016)","journal-title":"Med. Law"},{"issue":"3","key":"1891_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","volume":"113","author":"RL Avery","year":"2006","unstructured":"Avery, R.L., Pieramici, D.J., Rabena, M.D., Castellarin, A.A., Ma\u2019an, A.N., Giust, M.J.: Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113(3), 363\u2013372 (2006)","journal-title":"Ophthalmology"},{"issue":"20","key":"1891_CR7","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"CATT Research Group","year":"2011","unstructured":"CATT Research Group: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364(20), 1897\u20131906 (2011)","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"1891_CR8","doi-asserted-by":"publisher","first-page":"e0153052","DOI":"10.1371\/journal.pone.0153052","volume":"11","author":"AM Schauwvlieghe","year":"2016","unstructured":"Schauwvlieghe, A.M., Dijkman, G., Hooymans, J.M., Verbraak, F.D., Hoyng, C.B., Dijkgraaf, M.G., et al.: Comparing the effectiveness of bevacizumab to Ranibizumab in exudative age-related macular degeneration: The BRAMD study. PLoS One. 11(5), e0153052 (2016). https:\/\/doi.org\/10.1371\/journal.pone.0153052","journal-title":"PLoS One"},{"issue":"3","key":"1891_CR9","volume":"3","author":"SD Solomon","year":"2019","unstructured":"Solomon, S.D., Lindsley, K., Vedula, S.S., Krzystolik, M.G., Hawkins, B.S.: Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst. Rev. 3(3), CD005139 (2019)","journal-title":"Cochrane Database Syst. Rev."},{"key":"1891_CR10","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1038\/eye.2016.154","volume":"30","author":"A Shalaby","year":"2016","unstructured":"Shalaby, A., Lewis, K., Bush, K.: Licence to save: A UK survey of anti-VEGF use for the eye in 2015. Eye (Lond.) 30, 1404\u20131406 (2016). https:\/\/doi.org\/10.1038\/eye.2016.154","journal-title":"Eye (Lond.)"},{"key":"1891_CR11","unstructured":"Federatie Medisch Specialisten: Financi\u00eble impact aanbevelingen van de richtlijn Leeftijdsgebonden Maculadegeneratie (LMD): (2023). https:\/\/richtlijnendatabase.nl\/richtlijn\/budget-impact-analyse.pdf. Accessed 21 Nov 2024"},{"key":"1891_CR12","unstructured":"Zorginstituut Nederland: Maculadegeneratiemiddelen. Farmacotherapeutisch Kompas. n.d. https:\/\/www.farmacotherapeutischkompas.nl\/bladeren\/groepsteksten\/maculadegeneratiemiddelen. Accessed 21 Nov 2024"},{"key":"1891_CR13","unstructured":"The Guardian: Cheap blindness drug should be made widely available, says WHO, The Guardian:. (2015). https:\/\/www.theguardian.com\/society\/2015\/may\/17\/cheap-blindness-drug-should-be-made-widely-available-says-who. Accessed 21 Nov 2024"},{"key":"1891_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j779","volume":"356","author":"D Cohen","year":"2017","unstructured":"Cohen, D.: Roche asks WHO to remove Avastin from essential medicines list. BMJ 356, j779 (2017). https:\/\/doi.org\/10.1136\/bmj.j779","journal-title":"BMJ"},{"key":"1891_CR15","unstructured":"Federatie Medisch Specialisten: Richtlijn Leeftijdsgebonden Maculadegeneratie: \u2018Keuze van anti-VEGF middel.\u2019 (2023)"},{"key":"1891_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h1654","volume":"350","author":"D Cohen","year":"2015","unstructured":"Cohen, D.: Why have UK doctors been deterred from prescribing Avastin\u00ae? BMJ 350, h1654 (2015). https:\/\/doi.org\/10.1136\/bmj.h1654","journal-title":"BMJ"},{"key":"1891_CR17","unstructured":"Court of Justice of the European Union: F. Hoffmann-La Roche Ltd and Others v Autorit\u00e0 Garante della Concorrenza e del Mercato, Case C-179\/16 [Press release]: (2018)"},{"key":"1891_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1273","volume":"368","author":"C Dyer","year":"2020","unstructured":"Dyer, C.: Offering Avastin for wet AMD is legal, says appeal court. BMJ 368, m1273 (2020). https:\/\/doi.org\/10.1136\/bmj.m1273","journal-title":"BMJ"},{"key":"1891_CR19","unstructured":"Royal Courts of Justice: Case No: C1\/2018\/2744: (2020). https:\/\/www.judiciary.uk\/wp-content\/uploads\/2020\/03\/bayer-v-nhs-judgment-250320.pdf. Accessed 21 Nov 2024"},{"key":"1891_CR20","unstructured":"Paris Court of Appeals: Ruling of February 16: (2023). (2023). (No. 20\/14632) https:\/\/www.courdecassation.fr\/. Accessed 21 Nov 2024"},{"issue":"1","key":"1891_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1743517","volume":"12","author":"E Moorkens","year":"2020","unstructured":"Moorkens, E., Vulto, A.G., Huys, I.: An overview of patents on therapeutic monoclonal antibodies in Europe. MAbs 12(1), 1743517 (2020). https:\/\/doi.org\/10.1080\/19420862.2020.1743517","journal-title":"MAbs"},{"issue":"12","key":"1891_CR22","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1097\/IAE.0000000000003626","volume":"42","author":"PK Kaiser","year":"2022","unstructured":"Kaiser, P.K., Schmitz-Valckenberg, M.S., Holz, F.G.: Anti\u2013vascular endothelial growth factor biosimilars in ophthalmology. Retina. 42(12), 2243\u20132250 (2022)","journal-title":"Retina"},{"key":"1891_CR23","unstructured":"European Medicines Agency: Lytenava: EPAR \u2013 Product information: (2024). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lytenava-epar-product-information_en.pdf. Accessed 21 Nov 2024"},{"key":"1891_CR24","unstructured":"European Medicines Agency: Lytenava: EPAR \u2013 Public assessment report: (2024). https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/lytenava-epar-public-assessment-report_en.pdf. Accessed 21 Nov 2024"},{"key":"1891_CR25","unstructured":"CCMO: Een gerandomiseerd, enkele dosering, dubbelblinde parallelgroep, farmacokinetisch onderzoek waarbij ONS-1045 wordt vergeleken met twee vormen van Avastin\u00ae in gezonde mannelijke vrijwilligers: (2014)"},{"key":"1891_CR26","unstructured":"ClinicalTrials.gov: A clinical effectiveness study examining the efficacy and safety of ONS-5010 in subjects with neovascular age-related macular degeneration (NORSE ONE). ClinicalTrials.gov Identifier: NCT03844074: (2019). https:\/\/clinicaltrials.gov\/study\/NCT03844074. Accessed 21 Nov 2024"},{"key":"1891_CR27","unstructured":"ClinicalTrials.gov: A clinical effectiveness study examining the efficacy and safety of ONS-5010 in subjects with neovascular age-related macular degeneration (NORSE TWO). ClinicalTrials.gov Identifier: NCT03834753: (2019). https:\/\/clinicaltrials.gov\/study\/NCT03834753. Accessed 21 Nov 2024"},{"key":"1891_CR28","unstructured":"ClinicalTrials.gov: A safety and efficacy study of ONS-5010 for treating neovascular age-related macular degeneration (NORSE THREE). ClinicalTrials.gov Identifier: NCT04516278: (2020). https:\/\/clinicaltrials.gov\/study\/NCT04516278. Accessed 21 Nov 2024"},{"key":"1891_CR29","unstructured":"ClinicalTrials.gov: A 3-month study to compare the safety of ONS-5010 in vials versus pre-filled syringe in subjects with retinal disorders (NORSE SEVEN). ClinicalTrials.gov Identifier: NCT05112861. (2021). https:\/\/clinicaltrials.gov\/study\/NCT05112861. Accessed 21 Nov 2024"},{"key":"1891_CR30","unstructured":"ClinicalTrials.gov: A 3-month study to assess the safety and effectiveness of ONS-5010 in subjects with neovascular age-related macular degeneration (NORSE EIGHT). ClinicalTrials.gov Identifier: NCT06190093. (2025). https:\/\/clinicaltrials.gov\/study\/NCT06190093. Accessed 21 Nov 2024"},{"key":"1891_CR31","unstructured":"Outlook Therapeutics: ONS-5010 Clinical Progress. (n.d.). https:\/\/outlooktherapeutics.com\/lytenava-clinical-progress\/. Accessed 21 May 2025"},{"key":"1891_CR32","unstructured":"National Institute for Health and Care Excellence: Bevacizumab gamma for treating wet age-related macular degeneration: Final guidance: (2024)"},{"key":"1891_CR33","unstructured":"Zorginstituut Nederland: Advies sluisplaatsing Lytenava ooginjectie: (2024)"},{"key":"1891_CR34","unstructured":"International Association of Mutual Benefit Societies: A European drug pricing model for fair and transparent prices: (2021)"},{"issue":"7","key":"1891_CR35","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41571-018-0027-x","volume":"15","author":"CA de Uyl- Groot","year":"2018","unstructured":"de Uyl- Groot, C.A., L\u00f6wenberg, B.: Sustainability and affordability of cancer drugs: A novel pricing model. Nat. Rev. Clin. Oncol. 15(7), 405\u2013406 (2018). https:\/\/doi.org\/10.1038\/s41571-018-0027-x","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"1891_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.29245\/2572-9411\/2017\/1.1056","volume":"2","author":"MJ Nuijten","year":"2016","unstructured":"Nuijten, M.J., Vis, J.: Evaluation and valuation of innovative medicinal products. J. Rare Dis. Res. Treat. 2(1), 1\u20139 (2016)","journal-title":"J. Rare Dis. Res. Treat."},{"issue":"2","key":"1891_CR37","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/14737167.2022.1987219","volume":"22","author":"S van der Schans","year":"2022","unstructured":"van der Schans, S., De Loos, F., Boersma, C., Postma, M.J., B\u00fcller, H.: A novel perspective on pharmaceutical R&D costs: Opportunities for reductions. Expert Rev. Pharmacoecon. Outcomes Res. 22(2), 167\u2013175 (2022)","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"1891_CR38","doi-asserted-by":"publisher","unstructured":"Manders, E.A., van den Berg, S., de Visser, S.J., Hollak, C.E.: Drug pricing models, no \u2018one-size-fits-all\u2019 approach: A systematic review and critical evaluation of pricing models. Eur. J. Health Econ. 1\u201314 (2024).\u00a0https:\/\/doi.org\/10.1007\/s10198-024-01731-w","DOI":"10.1007\/s10198-024-01731-w"},{"key":"1891_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03446-w","volume":"19","author":"N Rosenberg","year":"2024","unstructured":"Rosenberg, N., Manders, E., van den Berg, S., et al.: Application of four pricing models for orphan medicines: A case study for lumasiran. Orphanet J. Rare Dis. 19, 485 (2024). https:\/\/doi.org\/10.1186\/s13023-024-03446-w","journal-title":"Orphanet J. Rare Dis."},{"key":"1891_CR40","unstructured":"U.S. Food and Drug Administration: Avastin (bevacizumab) [label information]. (2011). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125085s225lbl.pdf. Accessed 21 Nov 2024"},{"key":"1891_CR41","unstructured":"European Medicines Agency: Eylea: EPAR \u2013 Medicine overview: (2022). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/eylea-epar-medicine-overview_en.pdf. Accessed 21 Nov 2024"},{"key":"1891_CR42","unstructured":"European Medicines Agency: Mvasi: EPAR \u2013 Medicine overview: (2020). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/mvasi-epar-medicine-overview_en.pdf. Accessed 21 Nov 2024"},{"key":"1891_CR43","unstructured":"European Medicines Agency: Aybintio: EPAR \u2013 Medicine overview: (2021). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/aybintio-epar-medicine-overview_en.pdf. Accessed 21 Nov 2024"},{"key":"1891_CR44","unstructured":"European Medicines Agency: Equidacent: EPAR \u2013 Medicine overview: (2023). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/equidacent-epar-medicine-overview_en.pdf. Accessed 21 Nov 2024"},{"key":"1891_CR45","unstructured":"European Medicines Agency: Zirabev: EPAR \u2013 Medicine overview: (2020). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/zirabev-epar-medicine-overview_en.pdf. Accessed 21 Nov 2024"},{"key":"1891_CR46","unstructured":"European Medicines Agency: Alymsys: EPAR \u2013 Medicine overview: (2021). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/alymsys-epar-medicine-overview_en.pdf. Accessed 21 Nov 2024"},{"key":"1891_CR47","unstructured":"European Medicines Agency: Onbevzi: EPAR \u2013 Product information: (2021). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/onbevzi-epar-product-information_en.pdf. Accessed 21 Nov 2024"},{"key":"1891_CR48","unstructured":"European Medicines Agency: Oyavas: EPAR \u2013 Medicine overview: (2023). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/oyavas-epar-medicine-overview_en.pdf. Accessed 21 Nov 2024"},{"key":"1891_CR49","unstructured":"European Medicines Agency: Abevmy: EPAR \u2013 Medicine overview: (2023). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/abevmy. Accessed 21 Nov 2024"},{"key":"1891_CR50","unstructured":"European Medicines Agency: Vegzelma: EPAR \u2013 Product information: (2022). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vegzelma-epar-product-information_en.pdf. Accessed 21 Nov 2024"},{"key":"1891_CR51","unstructured":"European Medicines Agency: Avzivi: EPAR \u2013 Product information: (2024). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/avzivi-epar-product-information_en.pdf. Accessed 21 Nov 2024"},{"key":"1891_CR52","unstructured":"European Medicines Agency: Beovu: EPAR \u2013 Medicine overview: (2020). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/beovu-epar-medicine-overview_en.pdf. Accessed 22 Nov 2024"},{"key":"1891_CR53","unstructured":"World Bank: Population, total \u2013 OECD members: (2024). https:\/\/data.worldbank.org\/indicator\/SP.POP.TOTL?locations=OE. Accessed 4 Oct 2024"},{"key":"1891_CR54","doi-asserted-by":"publisher","unstructured":"OECD: Pharmaceutical Innovation and Access to Medicines. OECD Health Policy Studies. OECD, Publishing: (2018). https:\/\/doi.org\/10.1787\/9789264307391-en","DOI":"10.1787\/9789264307391-en"},{"key":"1891_CR55","unstructured":"European Parliament: Directive 2001\/83\/EC (Consolidated version 01\/01\/2025). Off J. Eur. Union. (2025). https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX%3A02001L0083-20250101 Accessed 21 Nov 2024 Council of the European Union"},{"key":"1891_CR56","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.jval.2024.06.015","volume":"27","author":"OJ Wouters","year":"2024","unstructured":"Wouters, O.J., Kesselheim, A.S., Kuha, J., Luyten, J.: Sales revenues for new therapeutic agents approved by the United States Food and Drug Administration from 1995 to 2014. Value Health 27, 1373\u20131381 (2024). https:\/\/doi.org\/10.1016\/j.jval.2024.06.015","journal-title":"Value Health"},{"key":"1891_CR57","unstructured":"Farmacotherapeutisch Kompas: Bevacizumab, intraveneus \u2013 Kosten. n.d. https:\/\/www.farmacotherapeutischkompas.nl\/bladeren\/preparaatteksten\/b\/bevacizumab__intraveneus_#kosten. Accessed 3 Dec 2024"},{"key":"1891_CR58","unstructured":"European Union: Regulation (EU) 2024\/568 of the European Parliament and of the Council of 7 February 2024 on fees and charges payable to the European Medicines Agency. Off. J. Eur. Union L 39, 1\u201339: (2024). https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX%3A32024R0568. Accessed 21 Nov 2024"},{"key":"1891_CR59","unstructured":"World Bank: Population, total \u2013 Netherlands: (2024). https:\/\/data.worldbank.org\/indicator\/SP.POP.TOTL?locations=NL. Accessed 16 Nov 2024"},{"key":"1891_CR60","unstructured":"World Bank: Population, total \u2013 European Union: (2024). https:\/\/data.worldbank.org\/indicator\/SP.POP.TOTL?locations=EU&year_high_desc=true. Accessed 3 Dec 2024"},{"key":"1891_CR61","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","volume":"47","author":"JA DiMasi","year":"2016","unstructured":"DiMasi, J.A., Grabowski, H.G., Hansen, R.W.: Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 47, 20\u201333 (2016)","journal-title":"J. Health Econ."},{"key":"1891_CR62","unstructured":"Jacobs, J., Livestro, D., Oosterwaal, M.: The cost of opportunity: A study on pharmaceutical R&D costs. Gupta Strategists (2019)"},{"issue":"3","key":"1891_CR63","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd3078","volume":"9","author":"SM Paul","year":"2010","unstructured":"Paul, S.M., Mytelka, D.S., Dunwiddie, C.T., Persinger, C.C., Munos, B.H., Lindborg, S.R., Schacht, A.L.: How to improve R&D productivity: the pharmaceutical industry\u2019s grand challenge. Nat. Rev. Drug Discov. 9(3), 203\u2013214 (2010)","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"1891_CR64","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2020.1166","volume":"323","author":"OJ Wouters","year":"2020","unstructured":"Wouters, O.J., McKee, M., Luyten, J.: Estimated research and development investment needed to bring a new medicine to market, 2009\u20132018. JAMA 323(9), 844\u2013853 (2020)","journal-title":"JAMA"},{"issue":"6","key":"1891_CR65","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.15445","volume":"7","author":"A Sertkaya","year":"2024","unstructured":"Sertkaya, A., Beleche, T., Jessup, A., Sommers, B.D.: Costs of drug development and research and development intensity in the US, 2000\u20132018. JAMA Netw. Open 7(6), e2415445 (2024). https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.15445","journal-title":"JAMA Netw. Open"},{"issue":"11","key":"1891_CR66","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamainternmed.2017.3601","volume":"177","author":"V Prasad","year":"2017","unstructured":"Prasad, V., Mailankody, S.: Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Internal Medicine 177(11), 1569\u20131575 (2017)","journal-title":"JAMA Internal Medicine"},{"key":"1891_CR67","doi-asserted-by":"publisher","first-page":"e4348","DOI":"10.1136\/bmj.e4348","volume":"345","author":"L D.W","year":"2012","unstructured":", L. D.W.,, L. J.R.: Pharmaceutical research and development: What do we get for all that money? BMJ. 345, e4348 (2012)","journal-title":"BMJ"},{"issue":"11","key":"1891_CR68","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s40273-021-01065-y","volume":"39","author":"M Schlander","year":"2021","unstructured":"Schlander, M., Hernandez-Villafuerte, K., Cheng, C.Y., Mestre-Ferrandiz, J., Baumann, M.: How much does it cost to research and develop a new drug? A systematic review and assessment. Pharmacoeconomics. 39(11), 1243\u20131269 (2021). https:\/\/doi.org\/10.1007\/s40273-021-01065-y","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1891_CR69","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom, S., Iorio, F., Eyers, P.A., Escott, K.J., Hopper, S., Wells, A., et al.: Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 18(1), 41\u201358 (2019)","journal-title":"Nat. Rev. Drug Discov"},{"key":"1891_CR70","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/534314a","volume":"534","author":"N Nosengo","year":"2016","unstructured":"Nosengo, N.: Can you teach old drugs new tricks? Nature. 534, 314\u2013316 (2016). https:\/\/doi.org\/10.1038\/534314a","journal-title":"Nature"},{"issue":"9","key":"1891_CR71","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jama.2020.0442","volume":"323","author":"FD Ledley","year":"2020","unstructured":"Ledley, F.D., McCoy, S.S., Vaughan, G., Cleary, E.G.: Profitability of large pharmaceutical companies compared with other large public companies. JAMA 323(9), 834\u2013843 (2020). https:\/\/doi.org\/10.1001\/jama.2020.0442","journal-title":"JAMA"},{"key":"1891_CR72","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/d41573-024-00131-2","volume":"23","author":"A Chandra","year":"2024","unstructured":"Chandra, A., Drum, J., Daly, M., Mirsberger, H., Spare, S., Neumann, U., et al.: Comprehensive measurement of biopharmaceutical R&D investment. Nat. Rev. Drug Discov. 23, 652\u2013653 (2024)","journal-title":"Nat. Rev. Drug Discov"},{"key":"1891_CR73","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-072080","volume":"380","author":"A Angelis","year":"2023","unstructured":"Angelis, A., Polyakov, R., Wouters, O.J., Torreele, E., McKee, M.: High drug prices are not justified by industry\u2019s spending on research and development. BMJ 380, e072080 (2023). https:\/\/doi.org\/10.1136\/bmj-2023-072080","journal-title":"BMJ"},{"key":"1891_CR74","unstructured":"Stichting Farma ter Verantwoording: Dagvaarding tegen AbbVie Inc., AbbVie B.V., AbbVie Deutschland GmbH & Co. KG. Rechtbank Amsterdam: Accessed 3 Feb 2025 (2023)"},{"issue":"8","key":"1891_CR75","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1136\/bjophthalmol-2019-314422","volume":"104","author":"JQ Li","year":"2020","unstructured":"Li, J.Q., Welchowski, T., Schmid, M., Mauschitz, M.M., Holz, F.G., Finger, R.P.: Prevalence and incidence of age-related macular degeneration in Europe: A systematic review and meta-analysis. Br. J. Ophthalmol. 104(8), 1077\u20131084 (2020). https:\/\/doi.org\/10.1136\/bjophthalmol-2019-314422","journal-title":"Br. J. Ophthalmol."},{"issue":"12","key":"1891_CR76","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.ophtha.2017.05.035","volume":"124","author":"JM Colijn","year":"2017","unstructured":"Colijn, J.M., Buitendijk, G.H.S., Prokofyeva, E., Alves, D., Cachulo, M.L., Khawaja, A.P., et al.: Prevalence of age-related macular degeneration in europe: The past and the future. Ophthalmology. 124(12), 1753\u20131763 (2017). https:\/\/doi.org\/10.1016\/j.ophtha.2017.05.035","journal-title":"Ophthalmology"},{"key":"1891_CR77","unstructured":"Zacks Equity Research: OTLK stock falls on failure to meet non-inferiority goal in AMD study. Nasdaq: (2024). https:\/\/www.nasdaq.com\/articles\/otlk-stock-falls-failure-meet-non-inferiority-goal-amd-study. Accessed 21 Nov 2024"},{"key":"1891_CR78","unstructured":"FirstWord, P.: Outlook Therapeutics\u2019 Lytenava\u00ae fails to demonstrate non-inferiority to ranibizumab in NORSE EIGHT trial. FirstWord Pharma (2024). https:\/\/firstwordpharma.com\/story\/5917040. Accessed 21 Nov 2024"},{"issue":"6","key":"1891_CR79","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1111\/bcp.14993","volume":"88","author":"A Cohen","year":"2022","unstructured":"Cohen, A., Ultee, R., van Veldhoven, G.: Making pharmaceutical companies report what matters about innovation. Br. J. Clin. Pharmacol. 88(6), 2583\u20132587 (2022). https:\/\/doi.org\/10.1111\/bcp.14993","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"1891_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41573-018-0006-2","volume":"18","author":"A Breckenridge","year":"2019","unstructured":"Breckenridge, A., Jacob, R.: Overcoming the legal and regulatory barriers to drug repurposing. Nat. Rev. Drug Discov. 18(1), 1\u20132 (2019). https:\/\/doi.org\/10.1038\/s41573-018-0006-2","journal-title":"Nat. Rev. Drug Discov."},{"key":"1891_CR81","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s40258-023-00816-6","volume":"21","author":"KH van der Pol","year":"2023","unstructured":"van der Pol, K.H., Aljofan, M., Blin, O., et al.: Drug repurposing of generic drugs: Challenges and the potential role for government. Appl. Health Econ. Health Policy 21, 831\u2013840 (2023). https:\/\/doi.org\/10.1007\/s40258-023-00816-6","journal-title":"Appl. Health Econ. Health Policy"},{"issue":"9","key":"1891_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104096","volume":"29","author":"SJ de Visser","year":"2024","unstructured":"de Visser, S.J., van den Berg, S., Mosterd, A., Lo, D.C.: Reliable business case for repurposing of existing medicines requires key changes in government policies. Drug Discov. Today 29(9), 104096 (2024). https:\/\/doi.org\/10.1016\/j.drudis.2024.104096","journal-title":"Drug Discov. Today"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-025-01891-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-025-01891-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-025-01891-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:02:25Z","timestamp":1790636545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-025-01891-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":82,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1891"],"URL":"https:\/\/doi.org\/10.1007\/s10198-025-01891-3","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work is part of the academic platform Medicine for Society, funded by the charity organization \u2018Vriendenloterij\u2019, which aims to improve the availability and affordability of (orphan) drugs. The publication of study results was not contingent on the sponsor\u2019s approval or censorship of the manuscript.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study did not involve human participants, animal subjects, or identifiable personal data.","order":2,"name":"Ethics","label":"Ethical statement","group":{"name":"EthicsHeading","label":"Declarations"}}]}}